Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression.

Gliomas are the most common primary brain tumours. Several independent studies have shown that isocitrate dehydrogenase 1 (IDH1) mutation in diffuse gliomas is associated with a more favourable patient outcome. The aim of this study was to evaluate the prognostic relevance of an antibody specifically detecting the R132H point mutation of IDH1 in tissue sections in a large series of human gliomas. Surgical specimens of 220 consecutive patients with infiltrative low and high-grade gliomas were included in this retrospective study. In multivariate analysis, IDH expression did not reach significance (p = 0.122) in regard to prognosis, in contrast to WHO grade and age at time of surgery (p < 0.001, Cox regression). A significant correlation of p53 expression to mutated IDH1 and histological grading and an inverse correlation to truncated EGFR expression were observed (p < 0.001, Mann-Whitney test). In sum, our results indicate that IDHR132H mutation correlates significantly with p53 and inversely with EGFR mutations. Further studies should investigate whether these correlations reflect involvement of these three molecules in a common signalling pathway.